Showing 1,401 - 1,420 results of 21,342 for search '(( significant ((rates decrease) OR (greater decrease)) ) OR ( significant decrease decrease ))', query time: 0.46s Refine Results
  1. 1401

    Changes in the active H3K27ac and repressive H3K27me3 histone marks among Vasa2+/Piwi1+ and all cells in fed, starved, and refed juvenile polyps. by Eudald Pascual-Carreras (12115380)

    Published 2025
    “…Between fed, T<sub>5ds</sub> and T<sub>20ds</sub> timepoints, MFI levels of H3K27ac progressively and significantly decreased while levels H3K27me3 (M) did not change significantly (N). …”
  2. 1402
  3. 1403

    The TOR inhibitors Rapamycin and AZD-8055 strongly reduce RPS6 phosphorylation and cell proliferation in Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

    Published 2025
    “…<i>n</i> = 2–4 biological replicates per condition, with 15 individuals per replicate. Significance levels for Student <i>t</i> test are indicated for adjusted <i>p</i> values: *<i>p</i> < 0.05, ***<i>p</i> < 0.001, ***<i>p</i> < 0.0001. d: day(s), n.s.: non-significant. …”
  4. 1404
  5. 1405
  6. 1406
  7. 1407
  8. 1408

    Study Data. by Jonathan S. Jahr (2709088)

    Published 2025
    “…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”
  9. 1409

    Study outcomes. by Jonathan S. Jahr (2709088)

    Published 2025
    “…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”
  10. 1410

    Patient characteristics. by Jonathan S. Jahr (2709088)

    Published 2025
    “…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”
  11. 1411
  12. 1412
  13. 1413
  14. 1414
  15. 1415
  16. 1416
  17. 1417
  18. 1418
  19. 1419
  20. 1420